A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Bruton's Tyrosine Kinase(BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/HAWKE/193
NMA SSA Reference Number: SSA/17/MonH/512
Monash Health Ref: RES-17-0000-590A
Effective start/end date30/04/1929/04/24


  • clinical trial
  • treatment efficacy
  • lymphoma